How does ApoA-1 Milano reduce plaque to reverse heart disease?

Question

How many percent of decrease in size of plaque and for how long? What's success rate?

especially for microvascular system.

Answer 1

ApoA-I Milano (Apolipoprotein) or aka HDL or the good cholesterol, which have been known long ago to reduce plaque inside the arteries (which causes heart diseases).

Cedars-Heart Center claims 30% reduction of the plaque in 5 weeks.

ApoA-I Milano is a naturally occurring mutant of ApoA-I, found in a family descended from a single couple of the 18th century.

First described in 1980, it was the first known molecular abnormality of apolipoproteins. Paradoxically, carriers of this mutation have very low HDL cholesterol levels, but no increase in the risk of heart disease.

Biochemically, ApoA-I contains an extra cysteine bridge, causing it to exist as a homodimer or as a heterodimer with ApoA-II. However, the enhanced cardioprotective activity of this mutant (which likely depends on cholesterol efflux) cannot easily be replicated by other cysteine mutants.

Recombinant Apo-I Milano dimers formulated into liposomes can reduce atheromas in animal models by up to 30%.

ApoA-I Milano has also been shown in small clinical trials to have a statistically significant effect in reducing (reversing) plaque build-up on arterial walls. In human trials the reversal of plaque build-up was measured over the course of five weeks.

Once-a-week intravenous administration of recombinant apo A-1 Milano (ETC-216) for five weeks led to a significant and measurable shrinkage of human coronary artery plaques as measured by intravascular ultrasound technique. These findings are unprecedented in that reversal of plaque size has been shown in five short weeks.

At this time, there are on-going studies for Apo A1-Milano. The process to produce this drug and design a study of this type can take several years. As of 2007, studies published in the internet (pubmed) are in phase II (of IV phases) clinical trials (hence covering a very small portion of the human population). Moreover, most of the studies done so far are in animals.

Answer 2

1

Answer 3

It makes the Cholesterol Slippery, and not sticky, it does not stick to artery walls or to each other, slippery cholesterol is good cholesterol, they do not stick together and form blockages! seeing as they have patented it, it most likely will be given the deep six, as it would wipe out all anti cholesterol sales worldwide.
if other researchers were to discover which gene in the family genome, created the protien, it could be distributed to everyone, as a gene therapy, and would make cholesterol problems a thing of the past.
most drug companies today, target profit, and address intervention aggressively!